A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
The primary objectives of the trial are to assess erythroid response to darbepoetin alfa, as determined by changes in hemoglobin and/or red blood cell (RBC) transfusion-dependence and to describe the safety profile of darbepoetin alfa in patients with MDS. The secondary objective is to assess bone marrow progenitor BFU-E growth before and after treatment with darbepoetin alfa.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Darbepoetin alfa
Phase: Phase 1/Phase 2
Ages Eligible For Study:
- Diagnosis: - Bone marrow aspirate/biopsy-proven MDS for > 2 months prior to enrollment. - MDS French-American-British (FAB) subtypes refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with excess blasts (RAEB), and non-proliferative chronic myelomonocytic leukemia (CMML) [WBC < 12,000/ml]. - Patients must have an untransfused hemoglobin < 10.0 g/dL and/or patients must be red cell transfusion-dependent for a period of at least 2 months prior to study entry. - Laboratory: - Bilirubin < or = to 2 mg/dL - ALT/SGPT < or = to 2.5 x the upper limit of normal (ULN) - Normal renal function (Stanford: serum creatinine < 1.2 mg/dL [male], < 1.0 mg/dL [female]; Vanderbilt: < 1.5 mg/dL). - Age: > or = to 18 - Other: - ECOG performance status 0-2. - Patients may receive standard supportive care, including transfusions and antibiotics as required. - Patients must be r-HuEPO naive or must not have received prior treatment with r-HuEPO > or = to 40,000 U/week for more than 4 weeks.